CAN NEUTROPHIL/LYMPHOCYTE RATIO BE USED AS AN INDICATOR OF INFLAMMATION IN PATIENTS WITH HYPERTHYROIDISM?

DA LI SE ODNOS NEUTROFILA/LIMFOCITA MOŽE KORISTITI KAO INDIKATOR UPALE KOD PACIJENATA SA HIPERTIREOIDIZMOM?

Murat Dağdeviren¹, Tolga Akkan¹, Dilek Yapar², Serdar Karakaya², Tanyel Dağdeviren³, Derun Ertuğrul¹, Mustafa Altay¹

¹University of Health Science, Keçiören Health Administration and Research Center, Department of Endocrinology and Metabolism, Ankara, Turkey
²University of Health Science, Keçiören Health Administration and Research Center, Department of Internal Medicine, Ankara, Turkey
³University of Health Science, Keçiören Health Administration and Research Center, Department of Family Practice, Ankara, Turkey

Summary

Background: In our study, we aimed to evaluate changes in the neutrophil and lymphocyte series and investigate whether the neutrophil/lymphocyte ratio (NLR) is indicative of inflammations in patients with hyperthyroidism.

Methods: A total of 161 patients were enrolled, 121 of which had hyperthyroidism (71 Graves’ Disease (GD) and 50 non-Graves hyperthyroidism (NGH) patients) and 40 of which were control group members. Retrospectively, patients’ neutrophil and lymphocyte counts were taken, and the NLR was calculated.

Results: While the number of neutrophils was significantly lower in the GD group (p = 0.003), there was no significant difference between the NGH and the control group. In the GD group, NLR values were significantly lower than the other two groups (median 1.39 for GD, median 1.84 for NGH and median 1.83 for the control group, p < 0.001). Only three patients in the GD group had neutropenia. There was also a significant negative correlation between free T3 and neutrophil count and NLR in hyperthyroid patients (r = -0.28, p = 0.001 and r = -0.34, p < 0.001, respectively).

Conclusions: In our study, we found that NLR did not increase in hyperthyroid patients and that this ratio decreased due to the decrease in neutrophil levels in GD. We thus concluded that NLR is not a suitable indicator of hyperthyroidism.

Keywords: hyperthyroidism, lymphocyte, neutrophil, ratio

Address for correspondence:
Dr. Murat Dağdeviren
Keçiören Training and Research Hospital, Department of Endocrinology and Metabolism, Pınarbağı neighborhood, 25 Ardahan street, zip code: 06280, Keçiören, Ankara, Turkey
Telephone: +90 312 356 90 00

Kratak sadržaj

Uvod: Cilj naše studije je bio da procenimo promene u seriji neutrofila i limfocita i istražimo da li je odnos neutrofila/limfocita (NLR) indikativan za upalu kod pacijenata sa hipertireoidizmom.

Metode: Ukupno je bio uključen 161 bolesnik, od kojih je 121 imao hipertireoidizam (71 sa Grejsovom bolešću (GD) i 50 njih sa hipertireoidizmom koji nije u vezi sa Grejsovom bolešću (NGH)), dok su 40 njih bili članovi kontrolne grupe. Retrospektivno su uzeti broj neutrofila i limfocita pacijenata i izračunat je NLR.

Rezultati: Dok je broj neutrofila bio značajno niži u GD grupi (p = 0,003), nije bilo značajne razlike između NGH i kontrolne grupe. U GD grupi su vrednosti NLR bile značajno niže od ostalih dvejru grupa (medijan 1,39 za GD, medijan 1,84 za NGH i medijan 1,83 za kontrolnu grupu, p < 0,001). Samo tri pacijenta u GD grupi su imala neutropeniju. Takođe, postojala je značajna negativna korelacija između slobodnog T3 i broja neutrofila i NLR kod hipertiroidnih pacijenata (r = -0,28, p = 0,001 i r = -0,34, p < 0,001, redom).

Zaključak: U našoj studiji smo otkrili da se NLR nije povećao kod hipertiroidnih pacijenata i da se taj odnos smanjio zbog smanjenja nivoa neutrofila u GD. Tako smo zaključili da NLR nije pogodan pokazatelj hipertireoidizma.

Ključne reči: hipertireoidizam, limfocit, neutrofil, odnos
Introduction

Thyrotoxicosis refers to a clinical condition resulting from inappropriate high thyroid hormone effects in tissues. Hyperthyroidism is a type of thyrotoxicosis due to increased hormone synthesis and secretion in the thyroid gland. The two most common causes of hyperthyroidism are Graves’ disease (GD) and toxic nodular goitre (1). The prevalence of hyperthyroidism is 0.8% in Europe and 1.3% in the USA (2, 3).

Hyperthyroidism is a form of inflammation caused by the systemic effects of increased thyroid hormones (4). This inflammation is much more evident in autoimmunity-related GD. Since antibodies against thyroid stimulating hormone (TSH) receptors primarily affect the thyroid, they also affect many cells such as adipocytes, fibroblasts, and bone cells (5, 6).

Neutrophil/lymphocyte ratio (NLR) has gained increasing importance in recent years and is an easily identifiable marker of inflammation (7). There are studies that NLR may be a marker of inflammation for a host of diseases such as familial Mediterranean fever, ankylosing spondylitis, rheumatic valve diseases, ulcerative colitis, psoriasis, coronary artery disease, malignancies, diabetes mellitus, hypertension, and chronic autoimmune thyroiditis (8–11). There are also opinions that NLR can be used for predicting progression and mortality, and that it can be used as a disease activity indicator for certain diseases (12). Considering these findings, it is conceivable that NLR may be an indicator of inflammation in patients with hyperthyroidism, which is an inflammatory disease. Although it is known that hyperthyroidism may cause changes in a number of hematological parameters, the relationship between hyperthyroidism with NLR and inflammation is not yet known (13). Therefore, we have aimed to evaluate the changes in the neutrophil and lymphocyte series in hyperthyroid patients, as well as to investigate whether NLR could be an indicator of inflammation in this study.

Materials and Methods

First of all, approval was asked for from the local ethical commission before beginning the study. The work was conducted according to the principles of the Helsinki Declaration, and a written consent concerning the study was obtained from each of the participants.

The study included 150 hyperthyroid patients who had applied to the Endocrinology Outpatient Clinic between January 1, 2014, and January 1, 2016, as well as 40 healthy volunteers who had also applied to the same outpatient clinics within the same date range. Twenty-nine patients with active infection or malignancy, alongside those who had previously received anti-thyroid drugs for any reason, were not included in the study. 71 of 121 hyperthyroid patients had GD. Participants were assessed accordingly to three groups: GD, non-GD hyperthyroidism (NGH) and control group. Data on age, gender, TSH, free T3, free T4, anti-thyroglobulin antibody (anti-Tg), anti-thyroid peroxidase antibody (anti-TPO), thyroid receptor antibody (TRAb), and whole blood counts were retrospectively obtained. Neutrophil and lymphocyte counts were determined, whereupon NLR values were calculated for each group.

Statistical analysis of the data was done using SPSS 22.0 software. For statistical significance, p < 0.05 was considered significant.

Descriptive statistics of patients and control groups were performed. Categorical values were reported in terms of number and percentage. Kolmogorov-Smirnov test and histogram graphs of the data were used to assess whether or not the data corresponded to normal distribution. Normal distributed data were expressed in terms of mean and standard deviation. Data that did not correspond to normal distribution were expressed in terms of median and minimum-maximum values. The Student’s t-test was used in order to assess countable data that met the normal distribution, and the Mann-Whitney U test was used to assess any countable data that did not fit the normal distribution. The Chi-Square test was used to compare the categorical variables. Pearson and Spearman correlation tests were applied during the analysis of correlations.

Results

69% of the GD group, 70% of the NGH group and 75% of the control group were female. There was no statistically significant difference between the groups regarding gender. There was no significant difference in age between the GD and NGH groups. The control group consisted of patients who were younger than those of the other two groups (median age of 45 for the GD, 45.5 for the NGH, and 33.5 for the control groups, p < 0.001). In the GD group, the number of neutrophils was significantly lower than the other two groups (p = 0.003). There was no significant difference in the number of neutrophils between the NGH and control groups. The NLR values in the GD group were significantly lower than the other two groups (median of 1.39 for the GD, 1.84 for the NGH, and 1.83 for the control groups, p < 0.001). There was no significant difference between NGH and control group in terms of NLR. Neutropenia was found in 3 patients in the GD group. However there was no neutropenia in the other two groups.

When the thyroid hormone and antibody parameters were examined, free T3 (fT3) values were significantly higher in the GD group than in the NGH group (9.11 versus 13.75; p = 0.001). There was no
A significant difference in free T4 (fT4) and TSH values between the two groups. TRAb, anti-TPO, and anti-Tg were significantly higher in the GD group (p = 0.03, p < 0.001 and p = 0.03, respectively). When the control, GD, and NGH groups were compared in terms of fT4 and TSH, it was found that the TSH values were significantly higher and the fT4 values were significantly lower in the control group (p < 0.001 and p < 0.001, respectively). The relevant data are provided in Table I.

![Figure 1](image1.png) *Figure 1 Correlation between fT3 and NLR.*

![Figure 2](image2.png) *Figure 2 Correlation between fT3 and neutrophil count.*

Significant differences were found only in fT3 levels between TRAb positive patients and TRAb negative patients (13.7 vs 9.8, p = 0.03). However, no significant difference was found in terms of other parameters.

When the hyperthyroid patients (GD and NGH) were evaluated together, there was a significant negative correlation between the fT3 and NLR, as well as between fT3 and neutrophil counts (r = –0.28, p =

---

**Table I** Demographic characteristics of groups, full blood count and NLR values.

<table>
<thead>
<tr>
<th></th>
<th>GD</th>
<th>NGH</th>
<th>Control</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>n</strong></td>
<td>71</td>
<td>50</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td><strong>Female (%)</strong></td>
<td>49 (69%)</td>
<td>35 (70%)</td>
<td>30 (75%)</td>
<td></td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td>45 (19–69)</td>
<td>45.5 (20–83)</td>
<td>33.5 (21–67)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Leukocyte count (cells/μL)</strong></td>
<td>6700 (3200–12300)</td>
<td>7400 (3900–13000)</td>
<td>7200 (4800–13000)</td>
<td>–</td>
</tr>
<tr>
<td><strong>Neutrophil count (cells/μL)</strong></td>
<td>3400 (1000–7500)</td>
<td>4000 (1800–9300)</td>
<td>4300 (2100–8100)</td>
<td>0.003</td>
</tr>
<tr>
<td><strong>Lymphocyte count (cells/μL)</strong></td>
<td>2400 (600–5300)</td>
<td>2250 (1100–4900)</td>
<td>2200 (1200–3600)</td>
<td>–</td>
</tr>
<tr>
<td><strong>NLR</strong></td>
<td>1.39 (0.41–5.33)</td>
<td>1.84 (0.97–4.92)</td>
<td>1.83 (1–4.26)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>fT3 (pg/mL)</strong></td>
<td>13.75 (3.01–30)</td>
<td>9.11 (4.47–30)</td>
<td>–</td>
<td>0.001</td>
</tr>
<tr>
<td><strong>fT4 (ng/mL)</strong></td>
<td>3.86 (1.01–10)</td>
<td>3.36 (1.14–9.20)</td>
<td>0.97 (0.68–1.49)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>TSH (μU/mL)</strong></td>
<td>0.004 (0.001–0.068)</td>
<td>0.005 (0.004–0.21)</td>
<td>2.08 (0.53–4.45)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>TRAb (U/L)</strong></td>
<td>4.81 (0.72–405)</td>
<td>3.47 (1.07–59)</td>
<td>–</td>
<td>0.03</td>
</tr>
<tr>
<td><strong>Anti-TPO (U/mL)</strong></td>
<td>154.65 (2.65–2000)</td>
<td>9.5 (0.7–1521)</td>
<td>–</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Anti-Tg (U/mL)</strong></td>
<td>46.07 (5–5000)</td>
<td>12.1 (5–1329)</td>
<td>–</td>
<td>0.03</td>
</tr>
</tbody>
</table>

and the detection of neutropenia in autoimmune thyroid patients suggests that immune reactions besides the hormone level may also be indicative of an important role in the development of neutropenia. However, no significant relationship was found between TRAb level and neutrophil count. Nevertheless, in some previous studies, a relationship between autoimmune thyroid disease and anti-neutrophil antibody (anti-PMN) was detected (16, 25). In 1985, Weitzman et al. (25) found that 50–55% of GD patients had a positive anti-PMN level, however, only 2% of them had neutropenia. Anti-PMN antibodies were detected in 37.2% of thyroid patients in the study of Kyritsi et al. (16), whereby the majority of which were autoimmune in origin. Considering previous studies in the literature, it can be considered that certain antibodies in addition to thyroid-related antibodies play a role in the development of some immunomedi­lated hematologic disorders in autoimmune thyroid diseases. In our study, PMN antibody levels were not measured.

There was no significant difference in lymphocyte levels between the groups in our study. There are some studies in the literature reporting changes in peripheral lymphocyte subgroups in thyroid diseases (26, 27). However, these studies have very insufficient and contradictory results.

There are reports that NLR can be used as a systemic inflammation marker in many diseases with inflammation. In the studies of Keskin et al. (11), NLR was found to be significantly higher in euthyroid Hashimoto patients, and moreover, this ratio also showed a positive correlation with the autoantibody level. In the study of Kocer et al. (28) NLR was significantly higher in patients with papillary thyroid cancer. However, there are studies with different results and that show that this ratio is not increased in papillary thyroid cancer (29). This data suggests that NLR may be used as an inflammatory marker in thyroid diseases as well as in other diseases. However, in our study, changes in the granulocyte series in Graves’ patients alongside no significant difference in NGH compared to the control group showed that NLR was not a suitable parameter to be used in these patients.

There are some restrictive factors in our study. First of all, our study was retrospective. Other inflammation markers such as sedimentation rate and C-reactive protein were not evaluated. Furthermore, the anti-PMN antibody level thought to play a role in the development of neutropenia was not examined at all.

Discussion

In our study, we found that the NLR did not increase in hyperthyroid patients and that this ratio decreased due to the reduction in neutrophil levels in Graves’ patients. Neutropenia is generally defined as having an absolute neutrophil count below 1500 cells/μL. However, there are opinions based on different figures (14). The effects of anti-thyroid drugs on the granulocytic series (agranulocytosis and neutropenia) are well known; however, the data on the direct effect of thyroid diseases on granulocytes are limited. In addition, data on lymphocyte subpopulation distributions in thyroid patients with or without neutropenia are also inadequate (15, 16). Indeed, the relationship between thyroidopathy and neutropenia dates back over 100 years (16). Subsequently, studies have been carried out in hyperthyroid patients with hematological disorders (such as leukopenia) (13, 17). In various studies, the prevalence of neutropenia in hyperthyroid patients was found to be between 14.1% and 30% (18–20). Recently, Aggerwal et al. (18) found that 29 of the 209 Graves’ patients were found to have neutropenia at the time of diagnosis. In this study and several previous small scale studies, neutropenia was also shown to improve after patients become euthyroid with treatment (17, 19, 21). The rate of neutropenia in our study is rather low compared to previous studies. 71 of 3 Graves’ patients (4.2%) had neutropenia (neutrophil < 1500). Ethnic differences within the patient populations as well as differences in the hyperthyroid levels of the patients (especially fT3 levels) in the studies may have caused this. The difference in neutropenic reference values (e.g. < 1800 and < 2000) may have led to this situation. In our study, the patients’ post-treatment status could not be assessed.

Three possible mechanisms in the thyroid-associated neutropenia are thought to play a role. These are humoral and cellular mechanisms as well as toxicity associated with direct thyroid hormone (16). Panossi et al. (22) have shown that a reduction in abnormal granulopoiesis and bone marrow granulocyte reserve in GD plays a role in the mechanism of neutropenia development. Shaw and Mehta (23) have also suspected that thyroid hormones might have an effect that directly inhibits the maturation and differentiation of pluripotent stem cells in the early stages of hematopoiesis. Moreover, experimental data has shown that normally high or low thyroid hormone exposure induces apoptosis of CD34+ progenitor cells (24). Furthermore, pernicious anemia, which may accompany autoimmune thyroid diseases, is thought to contribute to the development of neutropenia (16).

In our study, we found a negative correlation between fT3 and neutrophil levels in GD patients. This was a finding supporting the direct toxic effect of thyroid hormone levels on neutrophils. As a matter of fact, in a number of previous studies, a negative correlation between fT3 level and the number of neutrophils was found (16, 18). In our study, only the detection of neutropenia in autoimmune thyroid patients suggests that immune reactions besides the hormone level may also be indicative of an important role in the development of neutropenia. However, no significant relationship was found between TRAb level and neutrophil count. Nevertheless, in some previous studies, a relationship between autoimmune thyroid disease and anti-neutrophil antibody (anti-PMN) was detected (16, 25). In 1985, Weitzman et al. (25) found that 50–55% of GD patients had a positive anti-PMN level, however, only 2% of them had neutropenia. Anti-PMN antibodies were detected in 37.2% of thyroid patients in the study of Kyritsi et al. (16), whereby the majority of which were autoimmune in origin. Considering previous studies in the literature, it can be considered that certain antibodies in addition to thyroid-related antibodies play a role in the development of some immunomedi­lated hematologic disorders in autoimmune thyroid diseases. In our study, PMN antibody levels were not measured.

There was no significant difference in lymphocyte levels between the groups in our study. There are some studies in the literature reporting changes in peripheral lymphocyte subgroups in thyroid diseases (26, 27). However, these studies have very insufficient and contradictory results.

There are reports that NLR can be used as a systemic inflammation marker in many diseases with inflammation. In the studies of Keskin et al. (11), NLR was found to be significantly higher in euthyroid Hashimoto patients, and moreover, this ratio also showed a positive correlation with the autoantibody level. In the study of Kocer et al. (28) NLR was significantly higher in patients with papillary thyroid cancer. However, there are studies with different results and that show that this ratio is not increased in papillary thyroid cancer (29). This data suggests that NLR may be used as an inflammatory marker in thyroid diseases as well as in other diseases. However, in our study, changes in the granulocyte series in Graves’ patients alongside no significant difference in NGH compared to the control group showed that NLR was not a suitable parameter to be used in these patients.

There are some restrictive factors in our study. First of all, our study was retrospective. Other inflammation markers such as sedimentation rate and C-reactive protein were not evaluated. Furthermore, the anti-PMN antibody level thought to play a role in the development of neutropenia was not examined at all.
There was also a significant age difference between the hyperthyroid patients and the control group. However, there was no significant age difference between the GD and NGH groups. It is thought that age is not an important factor in the results.

In conclusion, we believe that it would be inappropriate to use NLR as an inflammation marker in patients with hyperthyroidism. Nevertheless, we feel that there is a need for more extensive work in this regard.

Conflict of interest statement
The authors stated that they have no conflicts of interest regarding the publication of this article.

References


